We are live on ! Find out more
FM

Frazier Management Portfolio holdings

AUM $1.12M
1-Year Est. Return 151.58%
This Fund
S&P 500
This Quarter Est. Return
+4.68%
1 Year Est. Return
+151.58%
3 Year Est. Return
+408.4%
5 Year Est. Return
+1,802.6%
10 Year Est. Return
–
AUM
$882M
AUM Growth
+$286M
Cap. Flow
+$377M
Cap. Flow %
42.79%
Top 10 Hldgs %
91.23%
Holding
26
New
6
Increased
1
Reduced
2
Closed
1

Top Buys

Rank Stock Value
1
ARQT icon
Arcutis Biotherapeutics
ARQT
+$283M
2
PASG icon
Passage Bio
PASG
+$78.3M
3
ADVM
Adverum Biotechnologies
ADVM
+$11.8M
4
SNDX icon
Syndax Pharmaceuticals
SNDX
+$9.3M
5
TRIL
Trillium Therapeutics Inc.
TRIL
+$9.24M

Top Sells

Rank Stock Value
1
COLL icon
Collegium Pharmaceutical
COLL
+$19.5M
2
ETTX
Entasis Therapeutics Holdings Inc.
ETTX
+$1.35M
3
KZR
Kezar Life Sciences
KZR
+$363K

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KZR
26
DELISTED
Kezar Life Sciences
KZR
– –
-9,058
Closed -$363K
1
2

Similar funds

ACMV
August Capital Management VI Palo Alto, California $1.39M AUM
FRCMI
First Round Capital Management III Philadelphia, Pennsylvania $418K AUM
DB
DCVC Bio Palo Alto, California $313K AUM
NAM
Newfleet Asset Management Hartford, Connecticut $2.05M AUM 27.28% 1-Year Est. Return
AP
Atlas Principals Charlotte, North Carolina $2.19M AUM 56.71% 1-Year Est. Return
ID
Inspire Developers Forest Hills, New York $4.07M AUM
CI
CMT Investments Chicago, Illinois $5M AUM 15.27% 1-Year Est. Return
DIF
Discovery Investment Fund Singapore $6.98M AUM

Frazier Management's Q1 2020 Portfolio in Review

As of Q1 2020, Frazier Management held 26 positions worth $882M, up 48% from $596M the previous quarter. Its ten largest holdings account for 91% of the portfolio.

Frazier Management deployed $377M of net new capital in Q1 2020, opening 6 new positions and adding to 1 existing holding. Its largest new stake was Arcutis Biotherapeutics: 10,542,790 shares worth $314M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Collegium Pharmaceutical, an estimated $19.5M trimmed.

  • Frazier Management's largest Q1 2020 buy was Arcutis Biotherapeutics: 10,542,790 shares worth $314M.
  • Frazier Management added most to Adverum Biotechnologies in Q1 2020, an estimated $11.8M increase.
  • Frazier Management's biggest Q1 2020 reduction was Collegium Pharmaceutical, cutting an estimated $19.5M.
  • Frazier Management fully exited Kezar Life Sciences in Q1 2020, selling an estimated $363K.
  • Frazier Management's ten largest holdings make up 91% of its $882M portfolio in Q1 2020.
  • Frazier Management opened 6 new positions and closed 1 in Q1 2020.
  • Frazier Management's portfolio value rose 48% quarter-over-quarter to $882M.

Based on Frazier Management's 13F filing for Q1 2020, filed 13 May 2020.